Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSB0254 in Advanced Solid Tumors
NCT04381325Phase 1Terminated
- Sponsor
- Transcenta
- Start
- Apr 2020
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MSB0254 in solid tumor (advanced stage), neuroendocrine tumors (NETs), Thymic squamous cell carcinoma (TSCC) and 2 more, sponsored by Transcenta. Primary endpoints: Safety and tolerability of MSB0254 and Maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D). Started Apr 2020; status: terminated.
02
Drugs
MSB0254
03
Conditions
solid tumor (advanced stage)neuroendocrine tumors (NETs)Thymic squamous cell carcinoma (TSCC)soft tissue sarcoma (STS)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04381325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04381325.